SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

AGM Statement

19 Dec 2023 07:00

RNS Number : 1950X
Tristel PLC
19 December 2023
 

Tristel plc

("Tristel", the "Company", or the "Group")

AGM Statement, notice of results and planned CEO succession

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at the offices of Cavendish, One Bartholomew Close, London EC1A 7BL.

 

Paul Swinney, Chief Executive Officer, will address the meeting with the following update:

 

"I am pleased to report that the Company has had a record first half with revenue for the six months ending 31 December 2023 expected to be £20.7m, an increase of 18% compared to £17.5m in the first half of last year. Revenue growth has been delivered across all our geographical markets. Gross margin remains above 80% in line with our expectations.

 

"In the United States, Parker Laboratories, our manufacturing and distribution partner, completed its first production run for Tristel ULT in early October, following receipt of our FDA approval in June 2023. This has enabled Parker to stock its national distribution network and provide product to the first beta site users. We expect to make steady progress in building our customer base throughout the United States during the second half of our financial year. We remain very excited about our prospects as we begin serving the largest healthcare market in the world.

 

"The business is performing strongly on all fronts and the confidence that we expressed in October in our medium-term outlook remains unchanged. With the growth possibilities for our business stronger than ever, and as a business with no debt and forecast cash balances of approximately £10.4m after payment of this year's final dividend on 22 December, we are in a strong position to capitalise upon our global leadership position in the medical device decontamination market." 

 

Notice of Results

The Company's unaudited interim results will be announced on 26 February 2024.

 

CEO succession planning

In addition, Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. Paul will continue in his post until a successor is appointed and has committed to remain available thereafter to support and advise the business in executing a successful transition in the leadership of the Group. The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates.

 

The Group's new CEO will join a strong executive leadership team with significant functional and market experience, gained from within and outside the business.

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Chief Financial Officer

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Charlotte Edgar

Mob: 07884 664 686

Alice Woodings

Mob: 07407 804 654

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash/Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEVLFFXLLXFBL
Date   Source Headline
27th Oct 20204:50 pmRNSIssue of Equity
19th Oct 20203:15 pmRNSDividend Timetable
19th Oct 20207:00 amRNSFinal Results
6th Oct 20207:00 amRNSNotice of Results
5th Oct 20204:41 pmRNSIssue of Equity
2nd Oct 20209:11 amRNSIssue of Equity
7th Sep 20201:16 pmRNSIssue of Equity
21st Aug 20207:00 amRNSTristel’s Duo for Ultrasound approved in India
7th Aug 202010:46 amRNSIssue of Equity
6th Aug 202010:30 amRNSUpdate from Virtual Shareholder Open Day
22nd Jul 20204:43 pmRNSDirector/PDMR Shareholding and Issue of Equity
22nd Jul 20209:05 amRNSSecond Price Monitoring Extn
22nd Jul 20209:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSTrading update
23rd Jun 20207:00 amRNSNotice of Trading update, Results & presentation
8th Jun 202010:40 amRNSIssue of Equity
22nd May 20209:47 amRNSIssue of Equity
28th Apr 20203:40 pmRNSIssue of Equity
27th Apr 20207:00 amRNSDirector Appointment
14th Apr 202010:02 amRNSIssue of Equity
7th Apr 202010:38 amRNSIssue of Equity
31st Mar 20208:00 amRNSHolding(s) in Company
25th Mar 202012:38 pmRNSHolding(s) in Company
23rd Mar 20209:05 amRNSSecond Price Monitoring Extn
23rd Mar 20209:00 amRNSPrice Monitoring Extension
23rd Mar 20207:00 amRNSLicense & Product Supply Agreement with Byotrol
20th Mar 20204:43 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:37 pmRNSPrice Monitoring Extension
13th Mar 20204:14 pmRNSIssue of Equity
10th Mar 202011:56 amRNSIssue of Equity
6th Mar 20201:42 pmRNSHolding(s) in Company
3rd Mar 202010:24 amRNSDirector/PDMR Shareholding and Issue of Equity
26th Feb 20207:00 amRNSHolding(s) in Company
25th Feb 20209:06 amRNSDirector/PDMR Shareholding (Replacement)
25th Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Feb 20207:00 amRNSHalf-year Report
20th Feb 202011:12 amRNSIssue of Equity
18th Feb 20209:51 amRNSIssue of Equity
30th Jan 20203:43 pmRNSIssue of Equity
15th Jan 20207:00 amRNSInvestor results presentation
14th Jan 20201:09 pmRNSIssue of Equity
17th Dec 201911:01 amRNSResult of AGM
17th Dec 20197:00 amRNSAGM Statement and notice of results
4th Dec 20199:30 amRNSIssue of Equity
3rd Dec 201911:20 amRNSHolding(s) in Company
26th Nov 20197:00 amRNSForthcoming Appointment of Non-Executive Chairman
20th Nov 201910:08 amRNSIssue of Equity
18th Nov 20197:00 amRNSUpdate on MobileODT strategic investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.